Correlations of MTHFR 677C>T polymorphism with cardiovascular disease in patients with end-stage renal disease: A meta-analysis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Gao, Xian Hui ^a   Zhang, Guo Yi ^a   Wang, Ying ^a   Zhang, Hui Ying ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ARTICLE; ASIAN; BLACK PERSON; CARDIOVASCULAR DISEASE; CAUCASIAN; CORRELATION ANALYSIS; END STAGE RENAL DISEASE; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; MTHFR GENE; PATHOGENESIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; RISK FACTOR;

CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY FAILURE, CHRONIC; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84904625469     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102323     Document Type: Article

References (43)

1. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E (2011) Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med, 171(2): 110-118.
2. Palacio S, Gonzales NR, Sangha NS, Birnbaum LA, Hart RG (2011) Thrombolysis for acute stroke in hemodialysis: international survey of expert opinion. Clin J Am Soc Nephrol, 6(5): 1089-1093.
3. Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S (2011) The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol, 22(2): 349-357.
4. McIntyre CW (2010) Haemodialysis-induced myocardial stunning in chronic kidney disease - a new aspect of cardiovascular disease. Blood Purif, 29(2): 105-110.
5. Weiner DE, Scott TM, Giang LM, Agganis BT, Sorensen EP, et al (2011) Cardiovascular disease and cognitive function in maintenance hemodialysis patients. Am J Kidney Dis, 58(5): 773-781.
6. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, et al (2010) Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol, 5(5): 905-911.
7. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, et al (2011) Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol, 6(4): 718-723.
8. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, et al (2010) Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol, 106(7): 963-968.
9. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, et al (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol, 3(2): 505-521.
10. Kendrick J, Chonchol MB (2008) Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol, 4(12): 672-681.
11. Chonchol M, Kendrick J, Targher G (2011) Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. Ann Med, 43(4): 273-282.
12. Cozzolino M, Biondi ML, Galassi A, Cusi D, Brancaccio D, et al (2010) Vascular calcification and cardiovascular outcome in dialysis patients: the role of gene polymorphisms. Blood Purif, 29(4): 347-351.
13. Fung MM, Salem RM, Lipkowitz MS, Bhatnagar V, Pandey B, et al (2012) Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC). Nephrol Dial Transplant, 27(1): 197-205.
14. Spellicy CJ, Northrup H, Fletcher JM, Cirino PT, Dennis M, et al (2012) Folate metabolism gene 5,10-methylenetetrahydrofolate reductase (MTHFR) is associated with ADHD in myelomeningocele patients. PLoS One, 7(12): e51330.
15. Garner JL, Niles KM, McGraw S, Yeh JR, Cushnie DW, et al (2013) Stability of DNA methylation patterns in mouse spermatogonia under conditions of MTHFR deficiency and methionine supplementation. Biol Reprod, 89(5): 125.
16. Field MS, Shields KS, Abarinov EV, Malysheva OV, Allen RH, et al (2013) Reduced MTHFD1 activity in male mice perturbs folate- and choline-dependent one-carbon metabolism as well as transsulfuration. J Nutr, 143(1): 41-45.
17. Hazra A, Kraft P, Lazarus R, Chen C, Chanock SJ, et al (2009) Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum Mol Genet, 18(23): 4677-4687.
18. Abbas S, Raza ST, Ahmed F, Ahmad A, Rizvi S, et al (2013) Association of Genetic polymorphism of PPARgamma-2, ACE, MTHFR, FABP-2 and FTO genes in risk prediction of type 2 diabetes mellitus. J Biomed Sci, 20(1): 80.
19. Zhang J, Qiu LX, Wang ZH, Wu XH, Liu XJ, et al (2010) MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls. Breast Cancer Res Treat, 123(2): 549-555.
20. Perna AF, Lanza D, Sepe I, Conzo G, Altucci L, et al (2013) Altered folate receptor 2 expression in uraemic patients on haemodialysis: implications for folate resistance. Nephrol Dial Transplant, 28(5): 1214-1224.
21. Lee SY, Kim HY, Park KM, Hong SG, Kim HJ, et al (2011) MTHFR C677T polymorphism as a risk factor for vascular calcification in chronic hemodialysis patients. J Korean Med Sci, 26(3): 461-465.
22. Heinz J, Kropf S, Luley C, Dierkes J (2009) Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis, 54(3): 478-489.
23. Fukasawa M, Matsushita K, Kamiyama M, Mikami Y, Araki I, et al (2003) The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis, 41(3): 637-642. (Pubitemid 36278381)
24. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, et al (2001) An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int, 60(3): 1106-1113. (Pubitemid 34205811)
25. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25(9): 603-605.
26. Zintzaras E, Ioannidis JP (2005) HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics, 21(18): 3672-3673. (Pubitemid 41264106)
27. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295(6): 676-680. (Pubitemid 43209069)
28. Aucella F, Margaglione M, Grandone E, Vigilante M, Gatta G, et al (2005) The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study. Nephrol Dial Transplant, 20(2): 382-386. (Pubitemid 40276895)
29. Haviv YS, Shpichinetsky V, Goldschmidt N, Atta IA, Ben-Yehuda A, et al (2002) The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron, 92(1): 120-126. (Pubitemid 34983885)
30. Ibrahim S, El Dessokiy O (2009) Prevalence of methylenetetrahydrofolate gene (MTHFR) C677T polymorphism among chronic hemodialysis patients and its association with cardiovascular disease: a cross-sectional analysis. Clin Exp Nephrol, 13(5): 501-507.
31. Kimura H, Gejyo F, Suzuki S, Miyazaki R (2000) The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. J Am Soc Nephrol, 11(5): 885-893. (Pubitemid 30241722)
32. Morimoto K, Haneda T, Okamoto K, Ishida H, Kikuchi K (2002) Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients [PMID: 11744804]. Nephron, 90(1): 43-50. (Pubitemid 34042840)
33. Yang Q, Bailey L, Clarke R, Flanders WD, Liu T, et al (2012) Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000 US adults. Am J Clin Nutr, 95(5): 1245-1253.
34. Clarke R, Bennett DA, Parish S, Verhoef P, Dotsch-Klerk M, et al (2012) Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med, 9(2): e1001177.
35. Pereira TV, Rudnicki M, Pereira AC, Pombo-de-Oliveira MS, Franco RF (2006) 5,10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15(10): 1956-1963. (Pubitemid 44664274)
36. Yun KU, Ryu CS, Oh JM, Kim CH, Lee KS, et al (2013) Plasma homocysteine level and hepatic sulfur amino acid metabolism in mice fed a high-fat diet. Eur J Nutr, 52(1): 127-134.
37. Benight NM, Stoll B, Chacko S, da Silva VR, Marini JC, et al (2011) B-vitamin deficiency is protective against DSS-induced colitis in mice. Am J Physiol Gastrointest Liver Physiol, 301(2): G249-259.
38. Di Minno MN, Tremoli E, Coppola A, Lupoli R, Di Minno G (2010) Homocysteine and arterial thrombosis: Challenge and opportunity. Thromb Haemost, 103(5): 942-961.
39. Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, et al (2009) Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev Neurother, 9(9): 1393-1412.
40. Stipanuk MH, Ueki I (2011) Dealing with methionine/homocysteine sulfur: cysteine metabolism to taurine and inorganic sulfur. J Inherit Metab Dis, 34(1): 17-32.
41. Safarinejad MR, Shafiei N, Safarinejad S (2011) Genetic susceptibility of methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C, and G1793A polymorphisms with risk for bladder transitional cell carcinoma in men. Med Oncol, 28 Suppl 1: S398-412.
42. Shemin D, Bostom AG, Selhub J (2001) Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis, 38(4 Suppl 1): S91-94. (Pubitemid 32927620)
43. Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, et al (2009) Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia, 29(8): 818-825.